AI Article Synopsis
- The study focuses on creating a 3D model of metastatic prostate cancer to better replicate the tumor microenvironment found in bones.
- Using a two-layer microfluidic system, researchers cultured fluorescently labeled metastatic prostate cancer cells alongside other relevant cell types, allowing uniform integration and easy tracking.
- The new culture method was found to reduce the proliferation rate of cancer cells while maintaining their viability, suggesting it could more accurately mimic how cancer grows in the bone environment.
Article Abstract
The niche microenvironment in which cancer cells reside plays a prominent role in the growth of cancer. It is therefore imperative to mimic the in vivo tumor niche in vitro to better understand cancer and enhance development of therapeutics. Here, we engineer a 3D metastatic prostate cancer model that includes the types of surrounding cells in the bone microenvironment that the metastatic prostate cancer cells reside in. Specifically, we used a two-layer microfluidic system to culture 3D multi-cell type spheroids of fluorescently labeled metastatic prostate cancer cells (PC-3 cell line), osteoblasts and endothelial cells. This method ensures uniform incorporation of all co-culture cell types into each spheroid and keeps the spheroids stationary for easy tracking of individual spheroids and the PC-3's residing inside them over the course of at least a week. This culture system greatly decreased the proliferation rate of PC-3 cells without reducing viability and may more faithfully recapitulate the in vivo growth behavior of malignant cancer cells within the bone metastatic prostate cancer microenvironment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2675053 | PMC |
| http://dx.doi.org/10.1016/j.biomaterials.2009.02.047 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of serum levels of irisin, tumor necrosis factor and some biochemical variables in males with prostate cancer in Baghdad City.
Cell Mol Biol (Noisy-le-grand)
January 2025
Al Door Technical Institute, Northern Technical University, Mosul, Iraq.
Prostate cancer is the most common type after the age of fifty. It affects males and affects the prostate gland, which protects the function of sperm by producing semen. The current study was designed to evaluate prostate cancer infection effects on some biomarkers such as irisin, Tumor necrosis factor-TNF-α, prostate acid phosphates -PAP, Glutathione-GSH, malondialdehyde-MDA, urea, and creatinine.
View Article and Find Full Text PDFVariants of the ABCG2 gene in Mexican mestizo patients with prostate cancer.
Cell Mol Biol (Noisy-le-grand)
January 2025
Departamento de Biología Molecular y Genómica y Departamento de Disciplinas Filosófico Metodológicas e Instrumentales. Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, México.
ABCG2 transporter protein is one of several markers of prostate cancer stem cells (PCSCs). Gene variants of ABCG2 could affect protein expression, function, or both. The aim of this study was to identify the genetic variability of the ABCG2 gene in Mexican patients with prostate cancer.
View Article and Find Full Text PDFComparative Analysis of Acquired Resistance to Bortezomib in Prostate Cancer Cells Using Proteomic and Bioinformatic Tools.
J Cell Mol Med
January 2025
Department of Medical Biology, Faculty of Medicine, Kutahya Health Sciences University, Kutahya, Turkey.
Chemotherapy is a potent tool against cancer, but drug resistance remains a major obstacle. To combat this, understanding the molecular mechanisms behind resistance in cancer cells and the protein expression changes driving these mechanisms is crucial. Targeting the Ubiquitin-Proteasome System (UPS) has proven effective in treating multiple myeloma and shows promise for solid tumours.
View Article and Find Full Text PDF…But Words Will Never Hurt Me.
Eur Urol
January 2025
Eastern Health Clinical School, Monash University, Melbourne, Australia; Cancer Services, Eastern Health, Melbourne, Australia; Biomedicine Discovery Institute Cancer Program, Prostate Cancer Research Group, Department of Anatomy and Developmental Biology, Monash University, Melbourne, Australia.
Re: Metastatic Hormone-sensitive Prostate Cancer and Combination Treatment Outcomes: A Review.
Eur Urol
January 2025
Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, IRCCS San Raffaele Scientific Institute, Milan, Italy; "Vita-Salute" San Raffaele University, Milan, Italy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!